title: [A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 3)--Report on clinical usefulness in epilepsy].
abstract: A Phase 3 clinical trial of 123I-Iomazenil (IMZ), a tracer which binds specifically to central-type benzodiazepine receptors (BZR), was performed, and the clinical usefulness of IMZ was evaluated in 121 patients with epilepsy (106 cases with partial epilepsy and 15 cases with generalized epilepsy). A regional abnormality in the BZR distribution was detected in late IMZ images in 20 of 24 cases without abnormal MRI and/or X-ray CT findings. Moreover, only 16 of these 20 cases showed abnormal findings in the cerebral blood flow (CBF) images. In partial epilepsy, abnormal regions in late IMZ images agreed or partially agreed with epileptic foci estimated from the clinical symptoms of epileptic seizures, interictal EEG, and MRI and/or X-ray CT findings in 76%, 70% and 96% of the cases detected. These regions also agreed or partially agreed with the estimated epileptic foci in 92% of the cases with foci estimated by combination of those three methods and in 72% of those estimated by ictal EEG. The agreement or partial agreement rates of late IMZ images with each of the other methods were higher than those of CBF images, although the differences were not significant. For surgically-proven epileptic foci without any abnormality in the CBF image, abnormal regions were detected in late IMZ images. These findings suggest that IMZ SPECT is a useful new tool for detecting epileptic foci based on the distribution of BZR in the brain.
authors.affiliation: Fukui Medical School, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Torizuka
authors.forename: K
authors.initials: K
authors.lastname: Uemura
authors.forename: M
authors.initials: M
authors.lastname: Toru
authors.forename: Y
authors.initials: Y
authors.lastname: Shinohara
authors.forename: T
authors.initials: T
authors.lastname: Nishimura
authors.forename: Y
authors.initials: Y
authors.lastname: Yonekura
authors.forename: J
authors.initials: J
authors.lastname: Nakagawara
authors.forename: H
authors.initials: H
authors.lastname: Matsuda
authors.forename: F
authors.initials: F
authors.lastname: Sakai
authors.forename: K
authors.initials: K
authors.lastname: Matsuda
authors.forename: H
authors.initials: H
authors.lastname: Fukuyama
authors.forename: K
authors.initials: K
authors.lastname: Morimoto
mesh_terms: D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging*; D004827:Epilepsy / Q000000981:diagnostic imaging*; D005260:Female; D005442:Flumazenil / Q000031:analogs & derivatives*; D058785:GABA-A Receptor Agonists; D006801:Humans; D007457:Iodine Radioisotopes; D007564:Japan; D008297:Male; D011237:Predictive Value of Tests; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D058785:GABA-A Receptor Agonists; D007457:Iodine Radioisotopes; D005442:Flumazenil; C063038:iomazenil